GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curative Biotechnology Inc (OTCPK:CUBT) » Definitions » Piotroski F-Score

Curative Biotechnology (Curative Biotechnology) Piotroski F-Score : 0 (As of Jun. 11, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Curative Biotechnology Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Curative Biotechnology has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Curative Biotechnology's Piotroski F-Score or its related term are showing as below:


Curative Biotechnology Piotroski F-Score Historical Data

The historical data trend for Curative Biotechnology's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curative Biotechnology Piotroski F-Score Chart

Curative Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 3.00 4.00 3.00

Curative Biotechnology Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A 3.00 N/A

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Net Income was -1.287 + -1.418 + -1.503 + -0.966 = $-5.17 Mil.
Cash Flow from Operations was -0.311 + -0.175 + 0.136 + -0.139 = $-0.49 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Mar22)
to the end of this year (Mar23) was
(2.197 + 2.034 + 2.008 + 2.089 + 2.132) / 5 = $2.092 Mil.
Total Assets at the begining of this year (Mar22) was $2.20 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.11 Mil.
Total Current Liabilities was $5.33 Mil.
Net Income was -2.596 + -1.016 + -0.936 + -1.396 = $-5.94 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Mar21)
to the end of last year (Mar22) was
(0 + 0 + 0 + 2.412 + 2.197) / 5 = $2.3045 Mil.
Total Assets at the begining of last year (Mar21) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.44 Mil.
Total Current Liabilities was $0.82 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Curative Biotechnology's current Net Income (TTM) was -5.17. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Curative Biotechnology's current Cash Flow from Operations (TTM) was -0.49. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar22)
=-5.174/2.197
=-2.35502959

ROA (Last Year)=Net Income/Total Assets (Mar21)
=-5.944/0
=

Curative Biotechnology's return on assets of this year was -2.35502959. Curative Biotechnology's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Curative Biotechnology's current Net Income (TTM) was -5.17. Curative Biotechnology's current Cash Flow from Operations (TTM) was -0.49. ==> -0.49 > -5.17 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=0/2.092
=0

Gearing (Last Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=0/2.3045
=0

Curative Biotechnology's gearing of this year was 0. Curative Biotechnology's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)=Total Current Assets/Total Current Liabilities
=0.108/5.332
=0.02025506

Current Ratio (Last Year: Mar22)=Total Current Assets/Total Current Liabilities
=0.435/0.821
=0.52984166

Curative Biotechnology's current ratio of this year was 0.02025506. Curative Biotechnology's current ratio of last year was 0.52984166. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Curative Biotechnology's number of shares in issue this year was 579.823. Curative Biotechnology's number of shares in issue last year was 322.8. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Curative Biotechnology's gross margin of this year was . Curative Biotechnology's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar22)
=0/2.197
=0

Curative Biotechnology's asset turnover of this year was 0. Curative Biotechnology's asset turnover of last year was . ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Curative Biotechnology has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Curative Biotechnology  (OTCPK:CUBT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Curative Biotechnology Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Curative Biotechnology's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Curative Biotechnology (Curative Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
1825 NW Corporate Boulevard, Suite 110, Boca Raton, FL, USA, 33431
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The company currently has ongoing programs in three therapeutic areas: Infectious Disease, Neuro-Oncology, and Degenerative Eye Disease.

Curative Biotechnology (Curative Biotechnology) Headlines

From GuruFocus